T1	condition 139 176	Trastuzumab-Associated Cardiotoxicity
T2	eligibility 668 715	patients with HER2-positive early breast cancer
T3	intervention 765 776	perindopril
T4	intervention 778 788	bisoprolol
T5	control 793 800	placebo
T6	intervention-participants 1150 1162	Thirty-three
T7	intervention-participants 1194 1196	31
T8	control-participants 1222 1224	30
T9	outcome 1367 1392	no serious adverse events
T10	outcome 1434 1481	left ventricular end diastolic volume increased
T11	outcome 1648 1663	decline in LVEF
